GLP-1s can help employers lower medical costs in 2 years, new study finds

GLP-1s can help employers lower medical costs in 2 years, new study finds


Packages of weight loss drugs Wegovy, Ozempic and Mounjaro.

Picture Alliance | Getty Images

The growing demand for diabetes and weight loss drugs like Mounjaro, Ozempic and Wegovy has helped fuel higher health costs for large employers. For many, the big question is whether the pricy medications known as GLP-1s will pay off by improving worker health and lowering overall health costs over time. Analysts at Aon say it’s already happening.  

“We’ve never seen anything like this, really,” said Greg Case, CEO of Aon, an employer benefits services firm. “There was a 44% reduction in major cardiovascular issues. There was substantial reduction in osteoporosis. There was substantial reduction in pneumonia of multiple types.”

Aon researchers found that within two years, improved health outcomes for patients who were taking GLP-1 drugs bends the cost curve on medical care for them and their employers. However, getting to those savings requires high upfront costs.

GLP-1s come at a list price of more than $1,000 per dose. As broader approval for the drugs spurs higher demand, it’s also causing employer drug spending to spike. Since 2023, GLP-1s have pushed costs up at a pace than high-priced specialty medications, which include costly cancer and autoimmune treatments, according to an analysis by Evernorth, a division of Cigna.

Aon analysts looked at medical claims data for 139,000 U.S.-based workers with employer health coverage who took GLP-1 medications between 2022 and 2024. Beyond the drug costs, the study found GLP-1 patients tend to incur higher medical costs in their first year on the drugs, with more doctor visits to monitor their treatment on the drug and to seek help for other issues such as sleep apnea and esophageal conditions like acid reflux.

“The increase comes about in the first 12 to 15 months,” Case said. “They’re getting remedies on things that actually are underlying conditions [of obesity].”

But by the end of the second year of treatment with the GLP-1 drugs, overall health care costs for patients taking them fell 7% on average, compared to workers with similar chronic conditions and obesity characteristics who were not taking the drugs, Aon found. For GLP-1 patients who maintained rigorous adherence to the drug regimen, the savings were up to 13%.  

The biggest driver of those savings was the reduction by more than 40% of major adverse cardiac events such as heart attacks and strokes, compared to patients who were not taking the drugs, as well as a reduction in the onset of diabetes. 

Case said with this data, Aon has been able to help clients understand the timeline for seeing a return on providing insurance coverage for GLP-1s for weight loss, in addition to Type 2 Diabetes.

“We saw every single place where the cost went down — and it’s stunning,” said Case. “You can do this in a way that has an ROI, that will literally be an economic return.”

Following its research, Aon has launched a subsidized GLP-1 weight management program for its own U.S. workforce, which includes weekly virtual wellness visits and home blood tests to help employees adhere to the drug regimen.

The company will present the full results of its study at the Milken Institute Global Conference on Monday.



Source

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO
Health

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. I’m back in New […]

Read More
Hims & Hers to acquire European telehealth platform in global expansion
Health

Hims & Hers to acquire European telehealth platform in global expansion

The Hims logo arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025.  Bloomberg | Bloomberg | Getty Images Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava in its push to expand globally. “We’re excited to take this moment to really accelerate both the European expansion, but […]

Read More
Speaker Mike Johnson says some Medicaid recipients will ‘choose’ whether to lose healthcare under House spending bill
Health

Speaker Mike Johnson says some Medicaid recipients will ‘choose’ whether to lose healthcare under House spending bill

Speaker Mike Johnson, R-La., on Sunday defended cuts to Medicaid in the budget bill House Republicans passed last month from allegations that millions of Americans could lose their access to the program, saying that “4.8 million people will not lose their Medicaid unless they choose to do so.” Johnson told NBC News’ “Meet the Press” that the […]

Read More